US14888U1016 - Common Stock
CATALYST PHARMACEUTICALS INC
NASDAQ:CPRX (9/16/2024, 8:04:35 PM)
After market: 20.45 +0.01 (+0.05%)20.44
+0.22 (+1.09%)
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 167 full-time employees. The company went IPO on 2006-11-08. The firm is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The firm is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
CATALYST PHARMACEUTICALS INC
355 Alhambra Circle, Suite 801
Coral Gables FLORIDA 33134
P: 13055292522
CEO: Patrick J. McEnany
Employees: 167
Website: https://catalystpharma.com/
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is not too expensive for the growth it is showing.
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock and is consolidating.
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.
Here you can normally see the latest stock twits on CPRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: